OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a report issued on Sunday. The firm set a “sell” rating on the stock.

Separately, Needham & Company LLC restated a “buy” rating and set a $4.25 price target on shares of OncoCyte in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, OncoCyte has a consensus rating of “Hold” and an average price target of $4.06.

OncoCyte Trading Up 2.3 %

OncoCyte stock opened at $3.15 on Friday. OncoCyte has a 12-month low of $2.08 and a 12-month high of $4.34. The business’s 50-day moving average price is $3.13 and its two-hundred day moving average price is $2.93.

OncoCyte (NASDAQ:OCX) last released its earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%. The business had revenue of $0.10 million during the quarter.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.